Roche's obinutuzumab reduced the risk of disease progression or death in people with a form of blood cancer

16.05.2013 | from F. Hoffmann-La Roche AG


F. Hoffmann-La Roche AG

16.05.2013, Roche today announced the first results from CLL11, a phase III study of the investigational medicine GA101 which is being conducted in collaboration with the German CLL Study Group (GCLLSG). The CLL11 study compared the combination of either GA101 or MabThera/Rituxan (rituximab) and chlorambucil, a standard chemotherapy, to chlorambucil alone in chronic lymphocytic leukemia (CLL). CLL is one of the most common forms of blood cancer and each year it causes approximately 75,000 deaths across the globe. The CLL11 study included elderly people with previously untreated CLL who were often not able to tolerate existing aggressive treatment options.

“People with CLL, particularly the elderly and those with additional medical problems, need new options,” said Sandra Horning, MD, Global Head, Clinical Development Hematology/Oncology. “As a former practicing hematologist, I believe GA101 has the potential to one day expand treatment options for people with CLL and we look forward to continuing to work with the FDA and health authorities around the world in an effort to bring GA101 to those in need.”

GA101 combined with chlorambucil demonstrated a significant 86% reduction in the risk of disease progression, relapse or death. Additionally, the length of time during which people lived without their disease worsening (median progression-free survival, PFS) was more than doubled (23 months compared to 10.9 months, HR=0.14, 95% CI 0.09-0.21, p <.0001) when compared to chlorambucil alone. The full data, including the comparison of MabThera/Rituxan plus chlorambucil with chlorambucil alone will be presented in an oral session at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago on Tuesday, June 4.

“Roche has played a significant role in revolutionizing the treatment of blood cancers. With GA101, our aim was to design a unique antibody that kills cancer cells directly and engages the patient’s own immune cells to help attack the cancerous cells,” said Pablo Umaña, Head of Roche Glycart AG. GA101 is the first Type II anti-CD20 medicine that is glycoengineered, which means specific sugar molecules in GA101 were modified (using GlycoMAb technology) to change its interaction with the body’s immune cells with the goal of helping the immune system remove cancer cells from the body. In addition, as a type II anti-CD20 antibody, GA101 binds to CD20 with the aim of killing cancerous cells directly.

Based on the CLL11 data, marketing applications have been submitted to regulatory authorities including the European Medicines Association (EMA) and the U.S. Food and Drug Administration (FDA). The FDA has granted GA101 ‘Breakthrough Therapy Designation’. This designation is designed to expedite the development and review of medicines intended to treat serious diseases and to help ensure patients have access to them through FDA approval as soon as possible.

Media Contact:
Alexander Klauser +41-61 688 88 88 +41 61 688 15 15

--- END press release Roche's obinutuzumab reduced the risk of disease progression or death in people with a form of blood cancer ---


More information and links:
  F. Hoffmann-La Roche AG (company entry)



Swissnewsnow.com

On Swissnewsnow.com are published media releases, information from Swiss companies and Swiss authorities.

HELP Media AG on social networks
Facebook Twitter Instagram LinkedIn Pinterest Flickr

Subscription

Publish your media releases as a subscription and benefit from two free media releases.

Subscription 10 media releases (+2 free)
Subscription now »

Publish media release

To publish your own press release on Swissnewsnow.com, click on the following link:

Publish media release now »

Contact

Email:
info@help.ch

Address:
HELP Media AG
Thurgauerstrasse 40, 8050 Zurich


Copyright © 1996-2024 HELP Media AG, CH-8050 Zurich. All statements without guarantee. Terms and Conditions, Terms of Use & Privacy Policy